Updated Jul 16, 2026
Yale Catriona is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $2.80M.
Catriona Yale is the Chief Development Officer at Akero Therapeutics, Inc., where she has been involved in various development initiatives. She has filed multiple SEC documents related to her role within the company.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 47.6K | — | |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 27.2K | — | |
| 2025-11-06 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 4.7K | $21.10 | $100K |
| 2025-11-06 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 3.5K | $28.35 | $100K |
| 2025-09-11 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 659 | $43.02 | $28K |
| 2025-07-16 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 1.3K | $53.47 | $72K |
| 2025-07-16 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 8.7K | $52.87 | $458K |
| 2025-07-16 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 10.0K | $19.87 | $199K |
| 2025-06-30 | AKRO | Akero Therapeutics, Inc. | A — Grant or award | 890 | $23.87 | $21K |
| 2024-12-18 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale [10b5-1] | 9.1K | $29.11 | $264K |
| 2024-12-18 | AKRO | Akero Therapeutics, Inc. | M — Option exercise [10b5-1] | 9.1K | $21.10 | $191K |
| 2024-12-18 | AKRO | Akero Therapeutics, Inc. | A — Grant or award [10b5-1] | 24.3K | $0.00 | |
| 2024-12-12 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 2.8K | $30.79 | $87K |
| 2024-11-19 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale [10b5-1] | 300 | $28.82 | $9K |
| 2024-11-19 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale [10b5-1] | 8.8K | $27.69 | $243K |
| 2024-11-19 | AKRO | Akero Therapeutics, Inc. | M — Option exercise [10b5-1] | 9.1K | $21.10 | $191K |
| 2024-11-08 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale [10b5-1] | 10.0K | $35.19 | $352K |
| 2024-11-08 | AKRO | Akero Therapeutics, Inc. | M — Option exercise [10b5-1] | 10.0K | $0.61 | $6K |
| 2024-11-01 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale [10b5-1] | 15.5K | $32.62 | $505K |
| 2024-11-01 | AKRO | Akero Therapeutics, Inc. | M — Option exercise [10b5-1] | 15.5K | $21.10 | $327K |
Catriona Yale is the Chief Development Officer at Akero Therapeutics, Inc., where she has been involved in various development initiatives. She has filed multiple SEC documents related to her role within the company.…
Recorded transactions: 0 open-market purchases () and 13 open-market sales ($2.80M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Yale Catriona profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.